Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

Conditions

• Alzheimer Disease
• Healthy

Eligibility Criteria

Sex

ALL

Age

18 Years - 90 Years

Healthy Volunteers

Accepted

Interventions

• Positron Emission Tomography (PET) using 11C-ER176 for TSPO and 18F-SMBT1 for MAO-B — DRUG
  Participants will receive PET with 11C-ER176 to measure microglia AND astrocytes and PET with 18F-SMBT1 to measure astrocytes.

Study Details

Inflammation occurs in many brain diseases including Alzheimer's disease. In Alzheimer's disease, an abnormal protein called amyloid starts accumulating decades before the start of forgetfulness. However, scientists have reported that inflammation but not amyloid is linked to forgetfulness and the topography of brain inflammation and tau buildup are closely correlated in patients with mild cognitive impairment due to Alzheimer's disease. New medications are under development to help healing and prevent permanent damage in the brain. To see if inflammation is improving or getting worse with these medications, investigators can watch inside of the brain using a special camera called positron emission tomography (PET). It is currently possible to watch inflammation in the brain by taking pictures of a molecule called translocator protein (TSPO). But the problem is that by imaging TSPO, investigators can catch changes in more than one kind of cells. The information is not specific to each cell type. Such vague information is not completely useful to monitor the effect of new medications for inflammation. This proposal attempts to develop a novel method to capture changes in each of two major players in inflammation, microglia and astrocytes. To do so, investigators will take selective pictures of one cell type by using a novel imaging agent for PET. Investigators will also take PET pictures of TSPO. Investigators will process these two kinds of PET pictures using advanced mathematical methods and extract specific information on microglia and astrocytes. Our novel method will be useful to monitor new therapies to treat inflammation in the brain.

Key Dates

Start date

Jan 20, 2023

Status verified

Mar 2026

Primary completion

Oct 31, 2027

Completion

Oct 31, 2028

Study Design

Enrollment

71 participants (estimated)

Arms

• Arm: Healthy subjects
  Healthy subjects
• Arm: Patients with Alzheimer's disease
  Patients with Alzheimer's disease

Primary Outcome Measure

The level of monoamine oxidase-B [ Time Frame: At the time of the PET scan ]

Central Contacts

• Joseph C. Masdeu, MD, PhD
  7134411150
  [email protected]
• Belen Pascual, PhD
  7134411150
  [email protected]

Locations (1)

Find similar trials in Houston, TX

Related Studies

• Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
  PHASE4 · Recruiting · University of Texas at Austin · Austin, Texas
• Longitudinal Early-onset Alzheimer's Disease Study Protocol
  Recruiting · Indiana University · Sun City, Arizona
• ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
  Recruiting · InSightec · Delray Beach, Florida
• Trial-Ready Cohort-Down Syndrome (TRC-DS)
  Recruiting · University of Southern California · Phoenix, Arizona